0.86
-0.0098(-1.13%)
Currency In USD
| Previous Close | 0.87 |
| Open | 0.87 |
| Day High | 0.93 |
| Day Low | 0.82 |
| 52-Week High | 1.65 |
| 52-Week Low | 0.7 |
| Volume | 266,974 |
| Average Volume | 209,980 |
| Market Cap | 66.46M |
| PE | -1.83 |
| EPS | -0.47 |
| Moving Average 50 Days | 0.93 |
| Moving Average 200 Days | 1.05 |
| Change | -0.01 |
If you invested $1000 in Clearside Biomedical, Inc. (CLSD) since IPO date, it would be worth $118.62 as of April 20, 2025 at a share price of $0.86. Whereas If you bought $1000 worth of Clearside Biomedical, Inc. (CLSD) shares 5 years ago, it would be worth $403.76 as of April 20, 2025 at a share price of $0.86.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire Inc.
Apr 01, 2025 11:05 AM GMT
ALPHARETTA, Ga., April 01, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today tha
Clearside Biomedical Announces Six Abstracts Accepted for Presentation at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting
GlobeNewswire Inc.
Mar 24, 2025 11:05 AM GMT
- Suprachoroidal Delivery Develops as Promising Mainstream Procedure for Treating Multiple Macular Diseases - - SCS Microinjector® Provides Targeted and Compartmentalized Delivery of Therapeutics Directly to the Retina - ALPHARETTA, Ga., March 24, 2
Clearside Biomedical’s Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit
GlobeNewswire Inc.
Mar 20, 2025 11:05 AM GMT
- Post-Hoc Analyses Provide Comparative Data on Rescue Criteria and Intervention-Free Rates for Tyrosine Kinase Inhibitors (TKIs) in Wet AMD Development - - Unique Ability to Re-Dose CLS-AX vs Rescue Supports Regulatory & Commercial Strategy - ALPHAR
Data not available